Chemical inhibitors of CAs (CAIs) such as AZ and AZ-based new compounds as single agent or combination therapy with synthesized aromatic sulfonamides such as 2-(4-sulfamoylphe- nyl-amino)-4,6-dichloro-1, 3, 5-triazine (TR1) and 4-[3-(N, N-dimethylaminopropyl) thioreidophenylsulfonylaminoethyl] benzenesulfonamide (GA15) with high affinity for CA9 have been shown to inhibit CA9 enzymatic activity and suppress the invasive capacity, decrease cell proliferation and induce apoptosis in human renal carcinoma and cervical cancer cells [11,12]. The gene discussed is CA9; the disease is cervical cancer.